KYTX

Kyverna Therapeutics, Inc.

Price Chart

Latest Quote

$8.62

+0.19 (+2.25%)

Current Price

Previous Close	$8.43
Open	$8.43
Day High	$8.65
Day Low	$8.35
Volume	871,825

Fetched: 2026-06-25T06:21:44

Stock Information

Shares Outstanding	60.80M
Total Debt	$33.76M
Cash Equivalents	$236.45M
Net Income	$-156.40M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$498.52M
EPS (TTM)	$-3.27
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$321.36M
Income	$-156.40M
Book/sh	$3.23
Cash/sh	$3.89
Employees	129

Financial Ratios

Quick Ratio	7.97
Current Ratio	8.15
Debt/Eq	17.26

Returns & Margins

ROA	-39.55%
ROE	-74.55%

Ownership

Insider Ownership	7.10%
Institutional Ownership	74.30%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.78
P/B	2.54

Analyst Data

Recommendation	none
Target Price	$30.40

Technical Indicators

SMA20	$8.07
SMA50	$8.83
SMA200	$7.95
RSI	54.33
ATR	0.4641

Shares Float	35.55M
Short Float	11.12%
Short Ratio	6.71
Volatility	1.96
Rel Volume	1.95

Performance History

Week	+1.99%
Month	-4.76%
Quarter	+4.19%
6 Months	+0.86%
YTD	-6.50%
Year	+157.05%
10 Years	-72.76%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-25	$8.20	1,578,943
2026-06-24	$8.62	871,900
2026-06-23	$8.43	519,600
2026-06-22	$8.30	911,800
2026-06-18	$8.07	1,474,200
2026-06-17	$8.04	811,500
2026-06-16	$7.92	598,400
2026-06-15	$8.15	581,000
2026-06-12	$8.06	646,600
2026-06-11	$7.87	562,500
2026-06-10	$7.66	527,600
2026-06-09	$7.85	729,600
2026-06-08	$7.71	651,600
2026-06-05	$7.47	617,400
2026-06-04	$7.95	631,600
2026-06-03	$7.82	816,300
2026-06-02	$7.90	1,614,300
2026-06-01	$8.22	671,600
2026-05-29	$8.52	614,900
2026-05-28	$8.65	777,000
2026-05-27	$8.59	586,400
2026-05-26	$8.61	982,000

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

📰 Latest News

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

Exec Edge • 2026-06-09T21:19:19Z

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

Motley Fool • 2026-06-08T18:54:25Z

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

BioPharma Dive • 2026-05-13T10:27:40Z

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA

MarketBeat • 2026-04-25T12:31:47Z

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

24/7 Wall St. • 2026-02-16T14:40:23Z

Kyverna Therapeutics Stock Up 41% in a Month: Here's Why

Zacks • 2025-12-30T12:58:00Z

Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects

Simply Wall St. • 2025-12-18T13:08:43Z

Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation Data

MT Newswires • 2025-12-17T13:53:43Z

Investors Parse Jobs Data, Look Ahead to Inflation Report as US Futures Rise Pre-Bell

MT Newswires • 2025-12-17T13:12:06Z

KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data

Zacks • 2025-12-16T15:10:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$7,025,000
Operating Revenue	$0	$0	$0	$7,025,000
Expenses
Interest Expense	$489,000	$142,000	$187,000	$65,000
Total Expenses	$169,827,000	$142,604,000	$62,406,000	$36,409,000
Other Income Expense	$-85,000	$-90,000	$-55,000	$-9,000
Other Non Operating Income Expenses	$-85,000	$-90,000	$-55,000	$-9,000
Net Non Operating Interest Income Expense	$8,605,000	$15,217,000	$2,095,000	$500,000
Interest Expense Non Operating	$489,000	$142,000	$187,000	$65,000
Operating Expense	$169,827,000	$142,604,000	$62,406,000	$36,409,000
General And Administrative Expense	$36,107,000	$30,131,000	$12,483,000	$8,007,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Net Interest Income	$8,605,000	$15,217,000	$2,095,000	$500,000
Interest Income	$9,094,000	$15,359,000	$2,282,000	$565,000
Normalized Income	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Net Income From Continuing And Discontinued Operation	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Total Operating Income As Reported	$-169,827,000	$-142,604,000	$-62,406,000	$-29,384,000
Net Income Common Stockholders	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Net Income	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Net Income Including Noncontrolling Interests	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Net Income Continuous Operations	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Pretax Income	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Interest Income Non Operating	$9,094,000	$15,359,000	$2,282,000	$565,000
Operating Income	$-169,827,000	$-142,604,000	$-62,406,000	$-29,384,000
Per Share
Diluted EPS	$-3.64	$-3.33	$-1.48	$-1.12
Basic EPS	$-3.64	$-3.33	$-1.48	$-1.12
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-159,019,000	$-125,202,000	$-58,472,000	$-27,777,000
Reconciled Depreciation	$1,799,000	$2,133,000	$1,707,000	$1,051,000
EBITDA (Bullshit earnings)	$-159,019,000	$-125,202,000	$-58,472,000	$-27,777,000
EBIT	$-160,818,000	$-127,335,000	$-60,179,000	$-28,828,000
Diluted Average Shares	$44,259,999	$38,334,571	$40,822,525	$25,803,889
Basic Average Shares	$44,259,999	$38,334,571	$40,822,525	$25,803,889
Diluted NI Availto Com Stockholders	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Research And Development	$133,720,000	$112,473,000	$49,923,000	$28,402,000
Selling General And Administration	$36,107,000	$30,131,000	$12,483,000	$8,007,000
Other Gand A	$36,107,000	$30,131,000	$12,483,000	$8,007,000

Fetched: 2026-06-25

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$232,276,000	$266,587,000	$-131,397,000	$-73,997,000
Total Assets	$293,826,000	$304,645,000	$75,195,000	$66,924,000
Total Non Current Assets	$10,873,000	$14,044,000	$14,531,000	$13,673,000
Other Non Current Assets	$5,454,000	$3,388,000	$3,921,000	$1,232,000
Current Assets	$282,953,000	$290,601,000	$60,664,000	$53,251,000
Other Current Assets	$3,700,000	$4,622,000	$3,121,000	$1,929,000
Cash Cash Equivalents And Short Term Investments	$279,253,000	$285,979,000	$57,543,000	$51,322,000
Cash And Cash Equivalents	$124,093,000	$96,621,000	$34,647,000	$37,735,000
Debt
Total Debt	$29,032,000	$8,242,000	$9,079,000	$10,564,000
Long Term Debt And Capital Lease Obligation	$25,063,000	$4,302,000	$6,159,000	$8,287,000
Long Term Debt	$24,743,000	-	-	-
Current Debt And Capital Lease Obligation	$3,969,000	$3,940,000	$2,920,000	$2,277,000
Liabilities
Total Liabilities Net Minority Interest	$61,550,000	$38,058,000	$206,592,000	$140,921,000
Total Non Current Liabilities Net Minority Interest	$25,063,000	$4,302,000	$186,733,000	$128,967,000
Current Liabilities	$36,487,000	$33,756,000	$19,859,000	$11,954,000
Payables And Accrued Expenses	$22,528,000	$24,933,000	$14,127,000	$7,701,000
Payables	$5,306,000	$4,624,000	$4,358,000	$1,451,000
Accounts Payable	$5,306,000	$4,624,000	$4,358,000	$1,451,000
Other Current Liabilities	-	-	$3,519,000	$565,000
Other Non Current Liabilities	-	-	-	$6,000
Non Current Deferred Liabilities	-	-	-	$0
Current Deferred Liabilities	-	-	-	$0
Equity
Common Stock Equity	$232,276,000	$266,587,000	$-131,397,000	$-73,997,000
Total Equity Gross Minority Interest	$232,276,000	$266,587,000	$-131,397,000	$-73,997,000
Stockholders Equity	$232,276,000	$266,587,000	$-131,397,000	$-73,997,000
Gains Losses Not Affecting Retained Earnings	$97,000	$105,000	$4,000	$-26,000
Other Equity Adjustments	$97,000	$105,000	$4,000	$-26,000
Retained Earnings	$-424,827,000	$-263,520,000	$-136,043,000	$-75,677,000
Preferred Securities Outside Stock Equity	-	$0	$180,574,000	$120,674,000
Other
Ordinary Shares Number	$60,389,893	$43,214,918	$43,115,244	$40,822,525
Share Issued	$60,389,893	$43,214,918	$43,115,244	$40,822,525
Tangible Book Value	$232,276,000	$266,587,000	$-131,397,000	$-73,997,000
Invested Capital	$257,019,000	$266,587,000	$-131,397,000	$-73,997,000
Working Capital	$246,466,000	$256,845,000	$40,805,000	$41,297,000
Capital Lease Obligations	$4,289,000	$8,242,000	$9,079,000	$10,564,000
Total Capitalization	$257,019,000	$266,587,000	$-131,397,000	$-73,997,000
Additional Paid In Capital	$657,005,000	$530,002,000	$4,642,000	$1,706,000
Capital Stock	$1,000	$0	$0	$0
Common Stock	$1,000	$0	$0	$0
Preferred Stock	$0	$0	$0	-
Long Term Capital Lease Obligation	$320,000	$4,302,000	$6,159,000	$8,287,000
Current Capital Lease Obligation	$3,969,000	$3,940,000	$2,920,000	$2,277,000
Pensionand Other Post Retirement Benefit Plans Current	$9,990,000	$4,883,000	$2,812,000	$1,411,000
Current Accrued Expenses	$17,222,000	$20,309,000	$9,769,000	$6,250,000
Net PPE	$5,419,000	$10,656,000	$10,610,000	$12,441,000
Accumulated Depreciation	$-3,750,000	$-3,672,000	$-2,488,000	$-1,618,000
Gross PPE	$9,169,000	$14,328,000	$13,098,000	$14,059,000
Leases	$936,000	$821,000	$645,000	$456,000
Other Properties	$6,937,000	$11,439,000	$11,693,000	$12,931,000
Machinery Furniture Equipment	$1,296,000	$2,068,000	$760,000	$672,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$155,160,000	$189,358,000	$22,896,000	$13,587,000
Non Current Accrued Expenses	-	-	-	$0
Non Current Deferred Revenue	-	-	-	$0
Current Deferred Revenue	-	-	-	$0

Fetched: 2026-06-25

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-154,845,000	$-116,455,000	$-53,031,000	$-36,881,000
Operating Activities
Operating Cash Flow	$-153,712,000	$-114,250,000	$-52,410,000	$-36,113,000
Cash Flow From Continuing Operating Activities	$-153,712,000	$-114,250,000	$-52,410,000	$-36,113,000
Operating Gains Losses	$60,000	-	-	-
Investing Activities
Capital Expenditure	$-1,133,000	$-2,205,000	$-621,000	$-768,000
Investing Cash Flow	$40,015,000	$-160,902,000	$-8,785,000	$-14,097,000
Cash Flow From Continuing Investing Activities	$40,015,000	$-160,902,000	$-8,785,000	$-14,097,000
Capital Expenditure Reported	$-1,128,000	$0	-	-
Financing Activities
Issuance Of Capital Stock	$140,608,000	$341,171,000	$59,900,000	$11,954,000
Financing Cash Flow	$141,168,000	$337,113,000	$58,118,000	$11,880,000
Cash Flow From Continuing Financing Activities	$141,168,000	$337,113,000	$58,118,000	$11,880,000
Net Other Financing Charges	$-619,000	$-3,361,000	$-1,646,000	-
Net Preferred Stock Issuance	$24,700,000	$0	$59,900,000	$11,954,000
Preferred Stock Issuance	$24,700,000	$0	$59,900,000	$11,954,000
Net Common Stock Issuance	$115,908,000	$341,171,000	$0	-
Common Stock Issuance	$115,908,000	$341,171,000	$0	-
Other
Repayment Of Debt	$-808,000	$-956,000	$-781,000	$-249,000
Interest Paid Supplemental Data	$415,000	$142,000	$187,000	$65,000
End Cash Position	$124,644,000	$97,173,000	$35,212,000	$38,289,000
Beginning Cash Position	$97,173,000	$35,212,000	$38,289,000	$76,619,000
Changes In Cash	$27,471,000	$61,961,000	$-3,077,000	$-38,330,000
Proceeds From Stock Option Exercised	$1,987,000	$259,000	$645,000	$175,000
Net Issuance Payments Of Debt	$-808,000	$-956,000	$-781,000	$-249,000
Net Long Term Debt Issuance	$-808,000	$-956,000	$-781,000	$-249,000
Long Term Debt Payments	$-808,000	$-956,000	$-781,000	$-249,000
Net Investment Purchase And Sale	$41,078,000	$-158,697,000	$-8,164,000	$-13,329,000
Sale Of Investment	$405,701,000	$331,300,000	$46,683,000	$43,166,000
Purchase Of Investment	$-364,623,000	$-489,997,000	$-54,847,000	$-56,495,000
Net PPE Purchase And Sale	$65,000	$-2,205,000	$-621,000	$-768,000
Sale Of PPE	$70,000	$0	-	-
Purchase Of PPE	$-5,000	$-2,205,000	$-621,000	$-768,000
Change In Working Capital	$-1,076,000	$7,857,000	$3,424,000	$-10,327,000
Change In Other Current Liabilities	$-3,339,000	$-2,399,000	$-1,679,000	$-1,078,000
Change In Other Current Assets	$-980,000	$-1,955,000	$-1,849,000	$-637,000
Change In Payables And Accrued Expense	$2,350,000	$13,712,000	$8,144,000	$-678,000
Change In Accrued Expense	$1,807,000	$12,976,000	$4,061,000	$-1,355,000
Change In Payable	$543,000	$736,000	$4,083,000	$677,000
Change In Account Payable	$543,000	$736,000	$4,083,000	$677,000
Change In Prepaid Assets	$893,000	$-1,501,000	$-1,192,000	$-909,000
Other Non Cash Items	$2,972,000	$2,544,000	$1,720,000	$1,411,000
Stock Based Compensation	$10,080,000	$8,357,000	$2,220,000	$929,000
Asset Impairment Charge	$648,000	$0	-	-
Amortization Of Securities	$-6,888,000	$-7,664,000	$-1,115,000	$-284,000
Depreciation Amortization Depletion	$1,799,000	$2,133,000	$1,707,000	$1,051,000
Depreciation And Amortization	$1,799,000	$2,133,000	$1,707,000	$1,051,000
Gain Loss On Sale Of PPE	$60,000	$0	-	$0
Net Income From Continuing Operations	$-161,307,000	$-127,477,000	$-60,366,000	$-28,893,000
Change In Other Working Capital	-	-	-	$-7,025,000

Fetched: 2026-06-25